Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PM2
The NM_001377540.1(SLMAP):c.62A>T(p.His21Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H21R) has been classified as Uncertain significance.
SLMAP (HGNC:16643): (sarcolemma associated protein) This gene encodes a component of a conserved striatin-interacting phosphatase and kinase complex. Striatin family complexes participate in a variety of cellular processes including signaling, cell cycle control, cell migration, Golgi assembly, and apoptosis. The protein encoded by this gene is a coiled-coil, tail-anchored membrane protein with a single C-terminal transmembrane domain that is posttranslationally inserted into membranes. Mutations in this gene are associated with Brugada syndrome, a cardiac channelopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2015]
SLMAP Gene-Disease associations (from GenCC):
Brugada syndrome
Inheritance: Unknown, AD Classification: SUPPORTIVE, LIMITED, NO_KNOWN Submitted by: Genomics England PanelApp, Orphanet, ClinGen
Gain of glycosylation at Y23 (P = 0.0041);Gain of glycosylation at Y23 (P = 0.0041);Gain of glycosylation at Y23 (P = 0.0041);Gain of glycosylation at Y23 (P = 0.0041);Gain of glycosylation at Y23 (P = 0.0041);